Inke Expands Its Reach in China with New DMF Approvals

As 2025 unfolds, Inke proudly announces a pivotal achievement in its global expansion strategy: the approval of Drug Master Files for Formoterol Fumarate and Indacaterol Maleate in China. These approvals represent a significant step forward in bringing high-quality inhalation APIs to one of the world’s most critical pharmaceutical markets.

China’s healthcare landscape has seen rapid evolution, driven by increasing demand for advanced respiratory therapies. By securing these DMF approvals, Inke is well-positioned to support this demand while contributing to the advancement of respiratory care.

A Commitment to Excellence and Market Expansion

Inke’s approvals highlight the company’s commitment to delivering rigorously tested APIs that meet global regulatory standards. Formoterol Fumarate and Indacaterol Maleate are essential components in the treatment of respiratory conditions, and their availability in China ensures that pharmaceutical partners can rely on proven quality and consistency for their formulations.

“With the approval of these DMFs, we are not just expanding our presence in China; we are reaffirming our dedication to providing the industry with reliable, innovative solutions,” said Inke’s Commercial Director.

Looking Ahead

This milestone is a reflection of Inke’s strategy to grow globally while maintaining a strong focus on compliance, sustainability, and innovation. As we continue to strengthen our position in key markets, we remain committed to enabling our partners to deliver better health outcomes worldwide.

For more information about Inke’s products and services, contact us at contact-inke@inke.es